Previous Article | Next Article 
Journal of Clinical Microbiology, June 2001, p. 2348-2350, Vol. 39, No. 6
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.6.2348-2350.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Antifungal Susceptibilities, Varieties, and Electrophoretic
Karyotypes of Clinical Isolates of Cryptococcus
neoformans from Brazil, Chile, and Venezuela
Belinda M.
Calvo,1
Arnaldo L.
Colombo,2
Olga
Fischman,2
A.
Santiago,3
L.
Thompson,4
Marcia
Lazera,5
Flavio
Telles,6
Kazutaka
Fukushima,7
Kazuko
Nishimura,7
Reiko
Tanaka,7
Makoto
Myiajy,7 and
M. Luiza
Moretti-Branchini8,*
Universidad del Zulia-Luz,
Maracaibo,1 and Hospital Clínico
de Caracas, Caracas,3 Venezuela;
Clínica Santa María, Santiago,
Chile4; Chiba University, Chiba,
Japan7; and Fundação Oswaldo
Cruz, Rio de Janeiro,5 Universidade
Federal de Paraná, Curitiba,6 and
Universidade Federal de São Paulo2
and Universidade Estadual de
Campinas,8 Campinas, Brazil
Received 10 July 2000/Returned for modification 28 August
2000/Accepted 8 April 2001
 |
ABSTRACT |
One hundred clinical isolates of Cryptococcus
neoformans from human immunodeficiency virus (HIV)-infected and
non-HIV-infected patients from Brazil, Chile, and Venezuela were
separated according to varieties and tested for antifungal
susceptibility. A high susceptibility to antifungal agents was observed
among all the isolates. The electrophoretic karyotyping of 51 strains
revealed good discrimination among Cryptococcus neoformans
var. neoformans strains.
 |
TEXT |
An increase in the incidence of
cryptococcosis has been reported in recent years and is associated with
the growing population of immunocompromised patients and the human
immunodeficiency virus (HIV) epidemic. In Brazil, 4.5% of all
opportunistic infections in AIDS patients have been reported as being
caused by Cryptococcus neoformans (6).
Distribution of serotypes and varieties is considered to be regionally
specific, but Cryptococcus neoformans var.
neoformans serotype A has been recovered from approximately 99% of all AIDS patients in most countries (7). The
evaluation of antifungal susceptibility of C. neoformans is
of great interest, considering the high frequency and the severe
clinical manifestations of this infection (1). DNA typing
methods have shown a high genetic heterogeneity among clinical and
environmental isolates of C. neoformans (3, 9).
Most studies in Latin America have been limited to clinical and
epidemiological aspects (10, 11), and only few
investigations have studied the molecular epidemiology of clinical
isolates from this area (3). Therefore, we studied clinical isolates of C. neoformans isolates from three
countries in South America according to their varieties, serotypes,
antifungal susceptibilities, and genomic diversity, as determined by
electrophoretic karyotype (EK).
One hundred clinical isolates C. neoformans from Brazil (69 isolates), Venezuela (20 isolates), and Chile (11 isolates) were investigated. Sixty strains were obtained from HIV-positive patients, 16 were obtained from HIV-negative patients, and for 24 patients, the
data on HIV status were not available. The isolates were identified to
species level based on micromorphological and biochemical
characteristics (5). Canavanine-glycine-bromthymol blue
agar medium was used for the differentiation of the varieties
(4), and serotyping was performed by slide agglutination
test (Crypto Check; Iatron Co., Japan). All the isolates were tested by
broth microdilution method, performed according to the NCCLS guidelines
(8) for amphotericin B (AMB), fluconazole (FLC),
itraconazole (ITC), and flucytosine (5FC). Broth microdilution testing
was performed with RPMI 1640 with L-glutamine, without
bicarbonate, and buffered with MOPS (morpholinepropanesulfonic acid) at
pH 7.0. Candida parapsilosis ATCC 22019 was included on each
test as quality control strain. Breakpoints for azole and 5FC MICs were
defined as the lowest drug concentration resulting in a prominent
decrease in turbidity, compared with that in the growth control
(drug-free) well. The AMB MICs were defined as the lowest concentration
able to inhibit any visual growth. Karyotype analysis was done by
counter-clamped homogeneous electrophoresis (CHEF DRII). The
chromosomal DNA extractions were prepared according to previous
protocols (3). Pulsed-field gel electrophoresis was
carried out at 6 V/cm at 13.5°C with pulses of 60 to 120 s for
27 h. A Saccharomyces cerevisiae chromosomal DNA size
standard was inserted in each gel as a molecular weight standard.
Isolates were considered different if any readily detectable band did
not match. A computer analysis program (Vilber Loumart, Marnes la
Valle, France) was used to determine a dendrogram based on the Dice
coefficient of similarity (5%).
Eighty-nine isolates were identified as C. neoformans var.
neoformans, and 11 were identified as Cryptococcus
neoformans var. gattii. All C. neoformans
var. gattii strains were from HIV-negative patients.
Serotyping of 62 isolates of C. neoformans var.
neoformans identified 60 (96.8%) strains as serotype A. Among the 11 C. neoformans var. gattii strains,
nine isolates were serotype B. No particular serotype distribution was
related to any geographic areas, although three isolates, serotype AD,
were found only among the Chilean isolates. Our data were consistent
with several reports in the literature that referred to C. neoformans var. neoformans serotype A as predominant
worldwide, especially in AIDS patients (7, 12). However,
detailed surveys are needed to ascertain the prevalence of serotypes in
Latin America countries.
All C. neoformans isolates were susceptible to AMB; 99% of
C. neoformans var. neoformans and 73% of
C. neoformans var. gattii isolates were
susceptible to FLC. For 5FC, 90% of the isolates were susceptible, 9%
were intermediate, and one strain, from Venezuela, was resistant. MIC
ranges for C. neoformans var. neoformans were as
follows, respectively: AMB, 0.125 and 0.5 µg/ml; FLC; 4 and 8 µg/ml; ITC, 0.06 and 0.125 µg/ml; 5FC, 4 and 4 µg/ml. MIC ranges for C. neoformans var. gattii were as follows:
AMB, 0.25 and 0.5 µg/ml; FLC, 8 and 16 µg/ml; ITC, 0.125 and 0.25 µg/ml; 5FC, 2 and 8 µg/ml. The susceptibility profiles of C. neoformans isolates obtained from HIV-infected and
non-HIV-infected patients, as well as those of the isolates from
different countries, were very similar and consistent with studies in
the literature (2; S. Cordoba, M. Melhem, S. Pukinskas, M. A. Martins, S. Nery, B. Calvo, W. Vivot, M. Soria, G. Davel, and L. L. Rodero, Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother.,
abstr. 1508, 1999). Of note, the MIC90s of azoles obtained
with C. neoformans var. gattii were higher than
the values obtained with C. neoformans var.
neoformans. However, these values represented only one tube
dilution; additional studies are needed for further conclusions.
EK was performed with 40 C. neoformans var.
neoformans strains (25 from Brazil, 10 from Venezuela, and 5 from Chile) and 11 C. neoformans var. gattii
strains (8 from Brazil and 3 from Venezuela). C. neoformans
var. neoformans presented 18 profiles, while only 3 were
observed with C. neoformans var. gattii. Among
the 25 Brazilian isolates of C. neoformans var.
neoformans, 9 profiles were identified. The Venezuelan
C. neoformans var. neoformans strains had six EK profiles represented by four unique profiles. Two of the predominant profiles of the Brazilian collection were also identified among Venezuelan strains. Interestingly, five distinctive profiles were observed only in the five Chilean C. neoformans var.
neoformans isolates. In a previous study, Franzot et al.
(3) also observed a broad diversity among Brazilian
isolates. In our study, among the 11 C. neoformans var.
gattii strains, EK identified three different profiles and
all 7 isolates from the Brazilian collection exhibited the same
profile. No association between EK profiles and HIV disease or
serotypes was observed (Fig. 1 and
2). The distances between the two
varieties and serotypes generated by Dice coefficients are shown in
Fig. 2. Among the 18 profiles revealed by EK for C. neoformans var. neoformans, proper profiles were observed in each country that were not identified in others. Thus, further analysis is necessary to evaluate the significance of geographic distribution in the molecular epidemiology of C. neoformans in Latin America.

View larger version (115K):
[in this window]
[in a new window]
|
FIG. 1.
EK profiles of C. neoformans var.
gattii and C. neoformans var.
neoformans. The serotypes are indicated above the lanes. PM,
molecular size; Sc, S. cerevisiae DNA marker.
|
|

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 2.
Dendrogram corresponding to Fig. 1. The values were
generated from the Dice coefficients and illustrate the relatedness of
varieties and serotypes of C. neoformans var.
neoformans and C. neoformans var.
gattii isolates. Numbers 2, 3, and 4 represent C. neoformans var. gattii serotypes B, C, and C,
respectively. Numbers 7, 8, 9, 10, and 11 represent C. neoformans var. neoformans serotypes AD, AD, A, D, and
A, respectively. Values at the top are percent similarity.
|
|
In conclusion, C. neoformans serotype A appeared to be the
most prevalent agent of cryptococcosis in Latin America. Despite minor
differences of antifungal susceptibility exhibited by the two varieties
of C. neoformans, most isolates were susceptible to all
drugs tested. Our results provide evidence of a higher diversity of
genotypes among C. neoformans var. neoformans
isolates than among C. neoformans var. gattii isolates.
 |
ACKNOWLEDGMENTS |
This study was supported by grants from Fundação de
Amparo à Pesquisa do Estado de São Paulo (FAPESP-
14.518-7), Conselho Nacional de Pesquisa e Desenvolvimento
Tecnológico (CNPq- 522144/96-9), Brazil, Japan International
Cooperative Agency (JICA), and Chiba University, Chiba, Japan.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Infectious
Diseases Division, Faculdade de Ciências Médicas,
Universidade Estadual de Campinas (UNICAMP), Cidade Universitária
Zeferino Vaz, 13083-970, Campinas, São Paulo, Brazil. Phone:
55-19-3788-7734. Fax: 55-19-3236-2092. E-mail:
moretti{at}hc.unicamp.br.
 |
REFERENCES |
| 1.
|
Barchiesi, F.,
R. Hollis,
S. A. Messer,
G. Scalise,
M. G. Rinaldi, and M. A. Pfaller.
1995.
Electrophoretic karyotype and in vitro antifungal susceptibility of Cryptococcus neoformans isolates from AIDS patients.
Diagn. Microbiol. Infect. Dis.
23:99-103[CrossRef][Medline].
|
| 2.
|
Franzot, S. P., and J. S. Hamdan.
1996.
In vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs.
Antimicrob. Agents Chemother.
40:822-824[Abstract].
|
| 3.
|
Franzot, S. P.,
J. S. Hamdan,
B. P. Currie, and A. Casedevall.
1997.
Molecular epidemiology of Cryptococcus neoformans in Brazil and the United States: evidence for both local genetic differences and a global clonal population structure.
J. Clin. Microbiol.
35:2243-2251[Abstract].
|
| 4.
|
Kwon-Chung, K. J.,
I. Polacheck, and J. E. Bennett.
1982.
Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C).
J. Clin. Microbiol.
15:535-537[Abstract/Free Full Text].
|
| 5.
|
Lacaz, C. S.,
E. Porto, and J. E. C. Martins.
1991.
Técnicas micológicas e imunológicas, p. 545-608.
In
Micologia médica. Fungos, actinomicetos e algas de interesse médico. Sarvier, Sao Paulo, Brazil.
|
| 6.
|
Ministério da Saúde.
1999.
Programa nacional de doenças sexualmente transmissíveis, Brasília.
Brasil. Bol. Epidemiol. AIDS.
anoI(01):44.
|
| 7.
|
Mitchell, T. G., and J. R. Perfect.
1995.
Cryptococcosis in the era of AIDS 100 years after the discovery of Cryptococcus neoformans.
Clin. Microbiol. Rev.
8:515-548[Abstract].
|
| 8.
|
National Committee for Clinical Laboratory Standards.
1997.
Reference method for broth dilution antifungal susceptibility testing for yeasts. Approved standard M27-A.
National Committee for Clinical Laboratory Standards, Wayne, Pa.
|
| 9.
|
Perfect, J. R.,
B. B. Magee, and P. T. Magee.
1989.
Separation of chromosomes of Cryptococcus neoformans by pulsed-field gel electrophoresis.
Infect. Immun.
57:2624-2627[Abstract/Free Full Text].
|
| 10.
|
Rozembaum, R.,
A. J. R. Gonçalves,
B. Wanke,
M. J. Caiuby,
H. Clemente,
M. S. Lazera,
P. C. F. Monteiro, and A. T. Londero.
1992.
Cryptococcus neoformans varieties as agents of cryptococcosis in Brazil.
Mycopathologia
199:133-136.
|
| 11.
|
Rozembaum, R., and A. J. R. Gonçalves.
1994.
Clinical epidemiological study of 171 cases of cryptococcosis.
Clin. Infect. Dis.
18:369-380[Medline].
|
| 12.
|
Steenbergen, J. N., and A. Casadevall.
2000.
Prevalence of Cryptococcus neoformans var. neoformans (serotype D) and Cryptococcus neoformans var. grubii (serotype A) isolates in New York City.
J. Clin. Microbiol.
32:1974-1976.
|
Journal of Clinical Microbiology, June 2001, p. 2348-2350, Vol. 39, No. 6
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.6.2348-2350.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Bijie, H., Dzierzanowska, D., Klimko, N. N., Letscher-Bru, V., Lisalova, M., Muehlethaler, K., Rennison, C., Zaidi, M., the Global Antifungal Surveillance Group,
(2009). Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-Year Analysis of Susceptibilities of Noncandidal Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing. J. Clin. Microbiol.
47: 117-123
[Abstract]
[Full Text]
-
Khan, Z. U., Randhawa, H. S., Kowshik, T., Chowdhary, A., Chandy, R.
(2007). Antifungal susceptibility of Cryptococcus neoformans and Cryptococcus gattii isolates from decayed wood of trunk hollows of Ficus religiosa and Syzygium cumini trees in north-western India. J Antimicrob Chemother
60: 312-316
[Abstract]
[Full Text]
-
Dannaoui, E., Abdul, M., Arpin, M., Michel-Nguyen, A., Piens, M. A., Favel, A., Lortholary, O., Dromer, F., the French Cryptococcosis Study Group,
(2006). Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.. Antimicrob. Agents Chemother.
50: 2464-2470
[Abstract]
[Full Text]
-
Jain, N., Wickes, B. L., Keller, S. M., Fu, J., Casadevall, A., Jain, P., Ragan, M. A., Banerjee, U., Fries, B. C.
(2005). Molecular Epidemiology of Clinical Cryptococcus neoformans Strains from India. J. Clin. Microbiol.
43: 5733-5742
[Abstract]
[Full Text]
-
Trilles, L., Fernandez-Torres, B., dos Santos Lazera, M., Wanke, B., Guarro, J.
(2004). In Vitro Antifungal Susceptibility of Cryptococcus gattii. J. Clin. Microbiol.
42: 4815-4817
[Abstract]
[Full Text]